Clearwater Capital Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Clearwater Capital Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,337	Closed	-$209K	–	160
2023 Q4	$209K	Buy	+3,337	New	+$184K	0.02%	146
2022 Q4	–	Sell	-3,233	Closed	-$211K	–	162
2022 Q3	$211K	Buy	+3,233	New	+$234K	0.03%	144
2022 Q1	–	Sell	-2,921	Closed	-$221K	–	171
2021 Q4	$221K	Buy	2,921 +359	+14%	+$31.4K	0.02%	157
2021 Q3	$287K	Buy	2,562 +356	+16%	+$44.7K	0.03%	140
2021 Q2	$357K	Sell	2,206 -5	-0.2%	-$608	0.04%	119
2021 Q1	$269K	Buy	2,211 +863	+64%	+$130K	0.03%	137
2020 Q4	$206K	Buy	+1,348	New	+$159K	0.03%	149

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clearwater Capital Advisors's CRSP Position: Q1 2024 in Review

Clearwater Capital Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 3,337 shares — an estimated $209K sold.

Clearwater Capital Advisors first reported a position in CRSP in Q4 2020 and held it in 7 quarters. The position peaked at $357K in Q2 2021. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

Clearwater Capital Advisors reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
Clearwater Capital Advisors sold 3,337 CRISPR Therapeutics shares in Q1 2024, an estimated $209K.
Clearwater Capital Advisors first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 7 quarters.
Clearwater Capital Advisors's CRISPR Therapeutics position peaked at $357K in Q2 2021.
484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Clearwater Capital Advisors's 13F filing for Q1 2024, filed 9 May 2024.